%0 Journal Article %T Efficacy and safety of margetuximab plus chemotherapy vs . trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study %A Zhang, Qingyuan %A Ouyang, Quchang %A Li, Wei %A Chiu, Joanne %A Yan, Min %A Lu, Yen-Shen %A Sun, Sanyuan %A Li, Huiping %A Du, Yingying %A Wang, Xujuan %A Sun, Tao %A Yin, Yongmei %A Wang, Haibo %A Ye, Feng %A Shen, Kunwei %A Wang, Jingfen %A Pan, Yueyin %A Wang, Shusen %A Yang, Jin %A Wu, Xiaohong %A Dai, Ming-Shen %A Cheng, Jing %A Teng, Yuee %A Su, Fang %A Wu, Xinhong %A He, Jingdong %A Fu, Peifen %A Yang, Lulu %A Xin, Yuan %A Wang, Xiaojia %A Jiang, Zefei %J Translational Breast Cancer Research %D 2022 %B 2022 %9 %! Efficacy and safety of margetuximab plus chemotherapy vs . trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study %K %X %U https://tbcr.amegroups.org/article/view/68480 %V 3 %P %@ 2218-6778